Brian Van Tine, MD, PhD, and Fadi Braiteh, MD, discuss unmet needs in the treatment of gastrointestinal stromal tumors (GISTs) and look to the future in terms of the evolving field.
Videos
Experts discuss the role of multidisciplinary management for patients with gastrointestinal stromal tumors (GISTs).
John N. Allan, MD, discusses a pooled analysis of 4 clinical trials with 4-year follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia and TP53 aberration deletion 17p or a TP53 mutation.
An expert in gastric cancers provides insight on the recent advances and future directions for the management of locally advanced and metastatic gastric cancers.
Dr John Marshall discuss the DESTINY-Gastric01 trial and the implications of the study results to clinical practice for HER2+ metastatic gastric cancer.
John Marshall, MD, reviews options for second- and later line therapies and considerations for treatment sequencing in patients with HER2+ gastric cancers.
Dr John Marshall discusses frontline systemic treatment options for metastatic HER2+ gastroesophageal junction cancer and gastric cancer in general.
An expert in gastric cancers describes when and for whom molecular testing should be done in patients with metastatic HER2+ gastric cancer, and which tests are move relevant to treatment decision-making.
John Marshall, MD, reviews the case of a patient with metastatic HER2+ (human epidermal growth factor receptor 2) gastroesophageal junction cancer.
Xiuning Le, MD, PhD, discusses the reasoning behind splitting the dose of poziotinib dose in order to reduce adverse effects and improve efficacy for the treatment of EGFR- or HER2 exon 20–positive non–small cell lung cancer.
Erika P. Hamilton, MD, discusses the data leading up to the Next MONARCH 1 study of abemaciclib plus tamoxifen or abemaciclib alone with metastatic breast cancer.
John Burke, MD, provides clinical pearls in the recognition in treatment of relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL).
John Burke, MD, reflects on current novel therapies used in the treatment of relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL).
John Burke, MD, reviews the practical implications and role of tafasitamab and lenalidomide in addition to reviewing significant results from the L-MIND trial.
John Burke, MD, considers factors for initiating second-line treatment in relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL).
John Burke, MD, discusses frontline treatment options for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL).
John Burke, MD, presents a case of a 76-year-old man with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL).
Experts discuss the treatment considerations for acute GVHD, the role of molecular testing, and considerations for steroid-refractory acute GVHD.
The experts discuss a case presentation of a 50-year-old woman with acute GVHD, risk factors for GVHD, and initial treatment options.
Nicolaus Kröger, MD, discusses the advantages of autologous stem cell transplant and allogeneic stem cell transplant compared with autologous tandem transplant in patients with multiple myeloma.
Jamile Shammo, MD, reviews initial treatment options for patients with low risk polycythemia vera.
Dr. Ruben Mesa and panel discuss the importance of and methods for risk assessment in patients with polycythemia vera.
Experts in MPN discuss diagnostic considerations for polycythemia vera.
Prithviraj Bose, MD, reviews the case of a 57-year-old man diagnosed with polycythemia vera.
Andrew Seidman, MD, reviews the case of a 45-year-old woman with HER2+ breast cancer, and the panel discusses initial treatment.
Michael Bishop, MD, discusses the investigations of and responses to chimeric antigen receptor T-cell therapy in different disease types.
A look toward the future development of bispecific T-cell engages (BiTEs) and CAR T-cell therapy for metastatic castration-resistant prostate cancer (mCRPC).
Toni Choueiri, MD, closes with promising new studies that will impact metastatic clear-cell renal cell carcinoma therapeutics in the years to come.
Both nivolumab + ipilimumab and lenvatinib + pembrolizumab TKI/IO combinations are discussed, with patient selection and appropriate use being the focus.
Dosing strategies to achieve strong efficacy and ameliorate adverse events with the combination of lenvatinib + pembrolizumab in metastatic clear-cell renal cell carcinoma.